Format

Send to

Choose Destination
Leuk Res. 2015 Aug;39(8):866-73. doi: 10.1016/j.leukres.2015.04.011. Epub 2015 Apr 27.

Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes.

Author information

1
Chair of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S Martino - IST, Genoa, Italy. Electronic address: dr.paolaminetto@gmail.com.
2
Chair of Hematology, Department of Internal Medicine (DiMI), University of Genoa, IRCCS AOU S Martino - IST, Genoa, Italy.

Abstract

Several genes with relevant pathogenetic and prognostic value have been identified in patients with myelodysplastic syndromes. Overexpression of WT1 at diagnosis has been associated with increased progression to acute myeloid leukemia and reduced leukemia free survival. Conversely, few data are available on the prognostic value of BAALC gene overexpression in AML and MDS patients. We evaluated the prognostic value of the combined expression of WT1 and BAALC genes at diagnosis in 86 MDS patients who had been stratified according to IPSS and R-IPSS scoring systems. Our results suggest that in the whole group of patients, low levels of both WT1 and BAALC were associated with a favorable outcome (3-year LFS 74.5%, median not reached), whereas patients presenting high expression levels of both genes had the worst prognosis (3-year LFS 0%, median 12 months, p<0.001). More specifically, molecular profiling was especially useful for intermediate 1 and intermediate-2/high risk groups. This study suggests that evaluating WT1 and BAALC gene expression at diagnosis may improve standard risk stratification and possibly refine the therapeutic approach for MDS patients.

KEYWORDS:

BAALC; Leukemia-free survival; MDS; Molecular analysis; Risk stratification; WT1

PMID:
26012361
DOI:
10.1016/j.leukres.2015.04.011
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center